Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis

Tomas Kalincik; Dana Horakova; Tim Spelman; Vilija Jokubaitis; Maria Trojano; Alessandra Lugaresi; Guillermo Izquierdo; Csilla Rozsa; Pierre Grammond; Raed Alroughani; Pierre Duquette; Marc Girard; Eugenio Pucci; Jeannette Lechner-Scott; Mark Slee; Ricardo Fernandez-Bolanos; Francois Grand'Maison; Raymond Hupperts; Freek Verheul; Suzanne Hodgkinson; Celia Oreja-Guevara; Daniele Spitaleri; Michael Barnett; Murat Terzi; Roberto Bergamaschi; Pamela McCombe; Jose Sanchez-Menoyo; Magdolna Simo; Tunde Csepany; Gabor Rum; Cavit Boz; Eva Havrdova; Helmut Butzkueven

Journal article

Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis

Tomas Kalincik, Dana Horakova, Tim Spelman, Vilija Jokubaitis, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo, Csilla Rozsa, Pierre Grammond, Raed Alroughani, Pierre Duquette, Marc Girard, Eugenio Pucci, Jeannette Lechner-Scott, Mark Slee, Ricardo Fernandez-Bolanos, Francois Grand'Maison, Raymond Hupperts, Freek Verheul, Suzanne Hodgkinson Show all

ANNALS OF NEUROLOGY | WILEY | Published : 2015

DOI: 10.1002/ana.24339

Download PDF

Abstract

OBJECTIVE: In patients suffering multiple sclerosis activity despite treatment with interferon β or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. However, no studies have directly compared the outcomes of switching to either of these agents. METHODS: Using MSBase, a large international, observational, prospectively acquired cohort study, we identified patients with relapsing-remitting multiple sclerosis experiencing relapses or disability progression within the 6 months immediately preceding switch to either natalizumab or fingolimod. Quasi-randomization with propensity score-based matching was used to select subpopulations with comparable baseline ..

View full abstract

University of Melbourne Researchers

Timothy Spelman Author Surgery - St Vincent's Hospital

Helmut Butzkueven Author Medicine - Royal Melbourne Hospital

Tomas Kalincik Author Medicine - Royal Melbourne Hospital

Related Projects (7)

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

TREATING PROGRESSIVE MULTIPLE SCLEROSIS

While there are numerous therapies for relapsing-remitting multiple sclerosis (MS), therapy for progressive MS remains elusive. This project..

Is MS treatment effective long-term?

Multiple Sclerosis is an illness affecting more than 20,000 Australians, and causes significant disability and social disruption in most suf..

CENTRE FOR TRANSLATIONAL NEUROSCIENCE: A MODULAR PLATFORM FOR TRANSLATING DISCOVERY INTO HEALTH OUTCOMES

Clinical Centre of Research Excellence in Translational Neuroscience will provide people, pathways and resources to create a novel platform ..

SELECTING OPTIMAL TREATMENT FOR PATIENTS WITH MULTIPLE SCLEROSIS

Multiple sclerosis is the most common cause of neurological disability among young people. With the increasing choice of therapies, the goal..

Multiple Sclerosis: Investigating the cause and differences in outcome

nan

Grants

Awarded by Multiple Sclerosis Research Australia Postdoctoral Fellowship

Awarded by National Health and Medical Research Council (NHMRC) Early Career Fellowship

Awarded by NHMRC Career Development Award

Awarded by NHMRC

Awarded by NHMRC Centre for Research Excellence

Awarded by Charles University in Prague Project Grant

Awarded by Czech Ministry of Health Project Grant

Funding Acknowledgements

This work was supported by the Multiple Sclerosis Research Australia Postdoctoral Fellowship (11-054, to T.K.), National Health and Medical Research Council (NHMRC) Early Career Fellowship (1071124, to T.K.), NHMRC Career Development Award (628856, to H.B.), NHMRC Project Grant (1032484, to H.B.), NHMRC Centre for Research Excellence (1001216, to H.B.), and MSBase Foundation. The MSBase Foundation is a not-for-profit organization that receives support from Merck Serono, Biogen Idec, Novartis Pharma, Bayer Schering, Sanofi-Aventis, and BioCSL. D.H. and E.H. are recipients of the Charles University in Prague Project Grant (PRVOUK-P26/LF1/4) and Czech Ministry of Health Project Grant (NT13237-4/2012).